September 20, 2005 StemCells was a top performer among biotech stocks on Tuesday, reporting a successful test that used neural stem cells to repair the spinal cords of mice, Novartis announced positive Phase III data on a novel drug for hypertension, Pfizer received a non-approvable letter from the FDA for its injected COX-2 inhibitor, European regulators suspended an omnibus vaccine from Sanofi-Aventis, Neurobiological Technologies sold a drug candidate for up to $48 million, and Clinical Data will buy Icoria for about $12.5 million in stock. After the Fed raised interest rates, the Centient Biotech 200 closed with a small loss, dropping about 4 points to close at 3878, a .09% decline. More details...
